Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

doi:10.1182/blood-2012-10-462879

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

Blood - 21 Mar 2013

Jourdan Eric, Boissel Nicolas, Chevret Sylvie, Delabesse Eric, Renneville Aline, Cornillet Pascale, Blanchet Odile, Cayuela Jean-Michel, Recher Christian, Raffoux Emmanuel, Delaunay Jacques, Pigneux Arnaud, Bulabois Claude-Eric, Berthon Céline, Pautas Cécile, Vey Norbert, Lioure Bruno, Thomas Xavier, Luquet Isabelle, Terré Christine, Guardiola Philippe, Béné Marie C, Preudhomme Claude, Ifrah Norbert, Dombret Hervé

Abstract excerpt

Not all patients with core binding factor acute myeloid leukemia (CBF-AML) display a good outcome. Modern risk factors include KIT and/or FLT3 gene mutations and minimal residual disease (MRD) levels, but their respective values have never been prospectively assessed. A total of 198 CBF-AML patients were randomized between a reinforced and a standard induction course, followed by 3 high-dose cytarabine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factors

Share to Cytarabine

Share to Drug Resistance, Neoplasm

Share to Genes, Neoplasm

Share to Leukemia, Myeloid, Acute

Share to Neoplasm, Residual

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 23321257
DOI: 10.1182/blood-2012-10-462879

Genes

FLT3
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.PMID 23321257Read ↗

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.Semantic proximity Read ↗

KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study.Semantic proximity Read ↗

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read ↗

KIT and FLT3-ITD Mutations Do Not Predict Outcomes in Pediatric Core-Binding Factor Acute Myeloid Leukemia: Findings from the C-HUANAN-AML-15 Multicenter Cohort StudySemantic proximity Read ↗

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseSemantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.Semantic proximity Read ↗

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.Semantic proximity Read ↗

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapySemantic proximity Read ↗

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.Semantic proximity Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.